Flexion (FLXN) Could Trade to $34 Following Data - RBC

Go back to Flexion (FLXN) Could Trade to $34 Following Data - RBC

Flexion Therapeutics Reports Primary Endpoint Met in Pivotal Phase 3 Trial of Zilrettaâ„¢ in Knee Osteoarthritis

February 16, 2016 4:01 PM EST

Primary endpoint at week 12 against placebo achieved p value of... More